Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Baltera Robert Jr. reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio director Robert Baltera Jr. received a grant of 336,904 Restricted Stock Units (RSUs) of common stock. Each RSU represents a right to one share and was awarded at $0.00 per share. The RSUs vest in three equal annual installments starting on June 10, 2026, contingent on his continued service, and his reported direct holdings after this grant are 336,904 shares.
PALISADE BIO, INC. director Robert Baltera Jr. has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The data provided shows no reported buy, sell, exercise, gift, tax withholding, or restructuring transactions, indicating purely administrative reporting at this stage.
Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 10, 2026, Wei received a grant of 592,300 RSUs of Palisade Bio common stock at no cash cost.
The filing also shows 20,200 RSUs converting into the same number of common shares as they vested on June 10, 2026. One line reports 613,355 common shares held directly after the RSU vesting, and another reports 593,155 shares after the new RSU grant. The RSU awards are subject to service-based vesting over three annual installments tied to future stockholder meetings or specified anniversaries, so Wei must remain in service for full delivery of shares.
Palisade Bio director Donald Allen Williams increased his equity stake through stock-based compensation rather than market trades. He received a grant of 1,498,900 restricted stock units (RSUs) that vest in three equal annual installments starting on the earlier of the 2027 annual stockholders meeting or the anniversary of June 10, 2026, subject to continued service. On June 10, 2026, 60,666 previously granted RSUs vested and were converted into Common Stock at no cash exercise price, contributing to direct ownership of 1,509,628 common shares and 121,334 remaining RSUs. He also has 3,000 additional shares held indirectly through his defined benefit plan.
PALISADE BIO director Emil Chuang reported equity-based compensation and an RSU vesting. On June 10, 2026, he exercised restricted stock units (RSUs) into 20,200 shares of common stock and received an additional grant covering 592,300 shares, both at a stated price of $0.00 per share.
The RSU grants are subject to service-based vesting. One grant vests in three equal annual installments starting on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, contingent on continued service. Another RSU grant vested in full on June 10, 2026.
Zwick Jordan Michael reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio director Jordan Michael Zwick reported receiving a grant of 336,904 shares of Common Stock in the form of Restricted Stock Units as compensation. These RSUs carry a zero dollar grant price and will vest in three equal annual installments starting on June 10, 2026, contingent on his continued service with the company. After this award, the filing shows Zwick holding 336,904 shares directly.
Palisade Bio, Inc. filed an initial Form 3 identifying Jordan Michael Zwick as a director of the company. The filing does not report any insider share purchases, sales, or other transactions, indicating this is a baseline beneficial-ownership statement rather than a record of new trading activity.
Palisade Bio, Inc. held its 2026 annual stockholder meeting and made several governance and capital structure changes. Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and total authorized capital stock from 307,000,000 to 457,000,000 shares, effective upon filing in Delaware.
The company’s stockholders also approved amended and restated 2021 equity incentive and employee stock purchase plans, non‑binding executive compensation, and equity awards for non‑employee directors. A new independent director, Jordan Zwick, was appointed to the Board and Audit Committee, with an initial restricted stock unit grant valued at $566,000 vesting over three years.
Palisade Bio, Inc. Schedule 13G: Soleus Capital Master Fund, L.P. and related Soleus entities report shared beneficial ownership of 9,353,687 shares of Palisade Bio common stock. The filing states this represents 5.4% of the class based on 173,579,670 shares outstanding as of May 7, 2026.
The report attributes the shares to the Master Fund and discloses the management and ownership chain (Soleus Capital, LLC; Soleus Capital Group, LLC; Soleus Capital Management, L.P.; Soleus GP, LLC) and Guy Levy as managing member. The filing includes customary disclaimers that the other entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) obligations.